Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis.

Abstract

Relapsing polychondritis and Sweet's syndrome are rare systemic inflammatory conditions. The authors present a patient who developed Sweet's syndrome 1 week after adalimumab therapy for refractory relapsing polychondritis. Coexistent relapsing polychondritis and Sweet's syndrome is rare, however, is likely to represent a true disease association and signifies a high risk of myelodysplasia. Antitumour necrosis factor α (TNFα) therapy is a treatment option in both relapsing polychondritis and Sweet's syndrome, and switching anti-TNFα agents may be feasible in the event of adverse reaction.

• Authors: Sarah Keidel, Aubretia McColl, Sally Edmonds
• Journal: BMJ case reports (BMJ Case Rep) Vol. 2011 (Dec 21 2011) ISSN: 1757-790X [Electronic] England
• PMID: 22670004 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal, Humanized
• Adalimumab

Topics

• Adalimumab
• Aged
• Anti-Inflammatory Agents (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
• Humans
• Male
• Polychondritis, Relapsing (drug therapy)
• Sweet Syndrome (chemically induced)